1. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with D4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril 2005; 84: 538-540. [
DOI:10.1016/j.fertnstert.2005.02.017]
2. Xiaomiao Zhao X, He Z, Mo Y, Chen X, Chen Y, Yang D. "Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age". Eur J Obstet Gynecol Reprod Biol 2011; 154: 187-191. [
DOI:10.1016/j.ejogrb.2010.10.021]
3. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143: 1076-1084. [
DOI:10.1210/endo.143.3.8691]
4. Das M, Gillott D, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 2122-2126. [
DOI:10.1093/humrep/den185]
5. Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004; 19: 2738-2741. [
DOI:10.1093/humrep/deh508]
6. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318-323. [
DOI:10.1210/jc.2003-030932]
7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004a; 19: 41-47. [
DOI:10.1093/humrep/deh098]
8. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil Steril 2004b; 81: 19-25. [
DOI:10.1016/j.fertnstert.2003.10.004]
9. Marshall K. Polycystic Ovary Syndrome: Clinical Considerations. Altern Med Rev 2001; 6: 272-292.
10. Panidis D, Katsikis I, Karkanaki A, Piouka A, Armeni K, Georgopoulos NA. Serum Anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum Follicle Stimulating Hormone (FSH) levels. Med Hypothes 2011; 77: 649-653. [
DOI:10.1016/j.mehy.2011.07.005]
11. Chanukvadze D, Kristesashvili J, Kvashilava N. Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH). Iran J Reprod Med 2012; 10: 307-314.
12. Marx TL, Mehta ME. Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term. Clev Clin J Med 2003; 70: 31-45. [
DOI:10.3949/ccjm.70.1.31]
13. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HE, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456- 488. [
DOI:10.1016/j.fertnstert.2008.06.035]
14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. [
DOI:10.1210/jc.2006-0178]
15. Carlsen SM, Vanky E, Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009; 24: 1732-1738. [
DOI:10.1093/humrep/dep074]